99% Pharmaceutical raw materials Ezetimibe in stock CAS NO.163222-33-1

.Lower Price with higher quality

We are sincerely responsible for the "product quality" and "After Service"

1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one
EZETIMIBE
ZETIA
Ezitimibe&Int
EzetimibeC24H21F2N03
(3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone, Sch-58235
1-(4-Flurophenyl)-(3R)-3-(4-flurophenyl)-(3S)-hydroxypropyl-(4S)-(4-hydroxyphenyl)-2-azetidinone
Ezetimide
SCH-58235

Aizawa also said that ezetimibe ezetimibe, ezetimibe, is the first selective cholesterolby Schering plough and Merck Co to jointly develop absorption inhibitor, this product is the first one to get American approved by the FDA selective inhibitors of cholesterol absorption. Commodity name "Yi suitable pure", "EZETROL".

Aizawa ezetimibe is a kind of new selective cholesterol absorption inhibitor,selective inhibitor was also the first intestinal cholesterol absorption, the mechanism of action and other lipid-lowering drugs (such as: statins, bile acid chelating agent,phenoxy acid derivative inhibitor and plant sterol esterification product) is not the same, the product through the brush border of the small intestine membranevesicle membrane protein (molecular weight 145X103) binding, inhibition of intestine to diet and bile transport to the gut of the absorption of cholesterol, lower the content of cholesterol in serum and liver. Unlike the bile acid chelating agent,ezetimibe does not affect cholesterol esters, other steroids (such as cholic acid),three glycerol and the absorption of fat soluble vitamins. Its pharmacological actionand acetyl coenzyme A- cholesterol acyltransferase (ACAT) and the inhibition ofLDL receptor (scavenger receptor) expression and No. Aizawa is absorbed in combination with ezetimibe after liver and glucuronic acid after the enterohepatic circulation, almost is specifically expressed in the intestinal mucosal cell. This product can be used alone or with HMG CoA reductase inhibitors (statins)combined with application in the treatment of primary (heterozygous familial and non familial hypercholesterolemia), homozygous familial hypercholesterolemia(HoFH), homozygous sitosterolemia (or plant sterol levels).

Aizawa also said that ezetimibe ezetimibe, ezetimibe, is the first selective cholesterolby Schering plough and Merck Co to jointly develop absorption inhibitor, this product is the first one to get American approved by the FDA selective inhibitors of cholesterol absorption. Commodity name "Yi suitable pure", "EZETROL".

Aizawa ezetimibe is a kind of new selective cholesterol absorption inhibitor,selective inhibitor was also the first intestinal cholesterol absorption, the mechanism of action and other lipid-lowering drugs (such as: statins, bile acid chelating agent,phenoxy acid derivative inhibitor and plant sterol esterification product) is not the same, the product through the brush border of the small intestine membranevesicle membrane protein (molecular weight 145X103) binding, inhibition of intestine to diet and bile transport to the gut of the absorption of cholesterol, lower the content of cholesterol in serum and liver. Unlike the bile acid chelating agent,ezetimibe does not affect cholesterol esters, other steroids (such as cholic acid),three glycerol and the absorption of fat soluble vitamins. Its pharmacological actionand acetyl coenzyme A- cholesterol acyltransferase (ACAT) and the inhibition ofLDL receptor (scavenger receptor) expression and No. Aizawa is absorbed in combination with ezetimibe after liver and glucuronic acid after the enterohepatic circulation, almost is specifically expressed in the intestinal mucosal cell. This product can be used alone or with HMG CoA reductase inhibitors (statins)combined with application in the treatment of primary (heterozygous familial and non familial hypercholesterolemia), homozygous familial hypercholesterolemia(HoFH), homozygous sitosterolemia (or plant sterol levels).

Aizawa also said that ezetimibe ezetimibe, ezetimibe, is the first selective cholesterolby Schering plough and Merck Co to jointly develop absorption inhibitor, this product is the first one to get American approved by the FDA selective inhibitors of cholesterol absorption. Commodity name "Yi suitable pure", "EZETROL".

Aizawa ezetimibe is a kind of new selective cholesterol absorption inhibitor,selective inhibitor was also the first intestinal cholesterol absorption, the mechanism of action and other lipid-lowering drugs (such as: statins, bile acid chelating agent,phenoxy acid derivative inhibitor and plant sterol esterification product) is not the same, the product through the brush border of the small intestine membranevesicle membrane protein (molecular weight 145X103) binding, inhibition of intestine to diet and bile transport to the gut of the absorption of cholesterol, lower the content of cholesterol in serum and liver. Unlike the bile acid chelating agent,ezetimibe does not affect cholesterol esters, other steroids (such as cholic acid),three glycerol and the absorption of fat soluble vitamins. Its pharmacological actionand acetyl coenzyme A- cholesterol acyltransferase (ACAT) and the inhibition ofLDL receptor (scavenger receptor) expression and No. Aizawa is absorbed in combination with ezetimibe after liver and glucuronic acid after the enterohepatic circulation, almost is specifically expressed in the intestinal mucosal cell. This product can be used alone or with HMG CoA reductase inhibitors (statins)combined with application in the treatment of primary (heterozygous familial and non familial hypercholesterolemia), homozygous familial hypercholesterolemia(HoFH), homozygous sitosterolemia (or plant sterol levels).